STAT
NOVEMBER 4, 2024
This is Part 5 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market. Lower prices are good news for patients seeking more affordable medications, but the change can sometimes take a while.
Pharmacy Is Right For Me
NOVEMBER 4, 2024
Meet Lila, a passionate fourth-year Pharm.D. student at Auburn University Harrison College of Pharmacy. During her APPE rotation with the American Association of Colleges of Pharmacy , Lila opened up about her inspiring journey to find the perfect pharmacy school and how, with the guidance of mentors, she discovered her true “Pharmily.” How did you choose your pharmacy school/college or graduate program?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
NOVEMBER 5, 2024
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
The Pharmacist
NOVEMBER 4, 2024
Any dispensations to provide financial relief for health bodies impacted by rising National Insurance contributions should include community pharmacy, Community Pharmacy England (CPE) has stressed. In a statement shared on Friday (1 November), Janet Morrison, CPE chief executive, said the negotiator was 'deeply concerned about the impact of the Autumn Budget on a pharmacy sector already […] The post Any National Insurance exemptions should include community pharmacy, says CPE appeared firs
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
STAT
NOVEMBER 6, 2024
The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca last week acknowledged that Leon Wang, an executive vice president who also oversees international operations for the drugmaker, was being investigated along with a “small number” of employees.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
PharmaVoice
NOVEMBER 8, 2024
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
The Pharmacist
NOVEMBER 4, 2024
Increases to Employers’ National Insurance Contributions (NIC) and National Living Wage (NLW) outlined in the Autumn Budget could cost an average community pharmacy premises more than £12,000 each year - totalling around £125m across the sector as a whole. The estimate is based on analysis by the Independent Pharmacies Association (IPA), which calculated the impact […] The post Budget changes could cost each pharmacy ‘£12k more a year’ appeared first on The Pharmacist.
STAT
NOVEMBER 5, 2024
Three independent pharmacies have filed separate lawsuits accusing GoodRx, which markets a prescription drug discount card, of conspiring with several pharmacy benefit managers to fix reimbursement fees, the latest skirmish over the opaque pharmaceutical supply chain in the U.S. At issue are the behind-the-scenes transactions involving generic drugs, which account for an estimated 90% of the prescriptions written in the U.S. and, consequently, represent a lucrative market.
Express Pharma
NOVEMBER 8, 2024
Quantiphi, an AI-first digital engineering company, and DDReg, a global leader in regulatory expertise, have announced a partnership aimed at addressing regulatory challenges faced by pharmaceutical, biotechnology, medical device, and cosmetics manufacturers. The collaboration seeks to expedite the process of bringing innovations to market by utilising artificial intelligence.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
NOVEMBER 6, 2024
Dupixent (dupilumab) has been approved by the European Medicines Agency (EMA) as the first treatment for young children with eosinophilic esophagitis in the EU. This authorisation is based on Phase III data which found that 68 percent of children aged one to 11 years given Dupixent (dupilumab) achieved histological disease remission at 16 weeks. This result was maintained for up to one year.
The Pharmacist
NOVEMBER 7, 2024
NICE has emphasised the importance of HRT in new guidance and clarified that cognitive behavioural therapy (CBT) should be an ‘add on’ treatment for menopausal symptoms. In its updated guidance, NICE has encouraged healthcare professionals to have ‘informed conversations’ with patients about the risks and benefits of HRT, and included a new ‘discussion aid’ to use […] The post New NICE guidance clarifies HRT as ‘first line treatment’ for menopause symptoms appeared first on The Pharmacist.
STAT
NOVEMBER 6, 2024
Want to self-prescribe a prescription drug? No problem! Some of the largest pharmaceutical companies in the U.S. are piloting websites that essentially sell their drugs directly to consumers. This unprecedented move launches a new dystopic era: pharmaceutical companies as health care provider, no pesky physician middlemen needed. It’s what the pharmaceutical industry has always wanted: They have long viewed physicians as inconvenient barriers between the company and their customers.
Express Pharma
NOVEMBER 7, 2024
On 7 November 2024, the U.S. Food and Drug Administration (FDA) announced a proposal to remove oral phenylephrine from over-the-counter (OTC) drugs marketed as nasal decongestants. The proposal follows an agency review that concluded oral phenylephrine is ineffective in providing temporary relief of nasal congestion. Until a final order is issued, however, companies may continue to sell OTC products containing oral phenylephrine for nasal decongestion.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
The Guardian - Pharmaceutical Industry
NOVEMBER 5, 2024
Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price AstraZeneca shares tumbled on Tuesday wiping £14bn off the value of Britain’s biggest drug maker, after a report that dozens of senior executives at its China unit could be implicated in an insurance fraud case in the country’s pharmaceutical sector. Also putting pressure on the share price, early data on AstraZeneca’s experimental weight loss pill published on Monday was described as “somewhat un
The Pharmacist
NOVEMBER 8, 2024
GP leaders in England will vote on whether to lobby NHS England to ‘appropriately’ fund dispensing in community pharmacies and to put an end to pitting the two sectors against each other. The national Local Medical Committee (LMCs) conference later this month will debate a motion focused on the ‘necessity’ of community pharmacy. However, the […] The post GP leaders to debate community pharmacy funding appeared first on The Pharmacist.
STAT
NOVEMBER 6, 2024
LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations. Novo’s third quarter performance will be seen as a win for the company, particularly after Eli Lilly — its rival in the booming obesity drug market — reported earnings last week that fell below forecasts.
Express Pharma
NOVEMBER 6, 2024
Rubicon Research has received approval from the Securities and Exchange Board of India (SEBI) to proceed with an Initial Public Offering (IPO). The IPO will include a fresh issue of equity shares worth Rs 500 crore and an Offer For Sale (OFS) of shares valued at Rs 585 crore, sold by General Atlantic Singapore RR Pte, Rubicon’s promoter, as outlined in the Draft Red Herring Prospectus (DRHP) filed in July 2024.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Channels
NOVEMBER 4, 2024
Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. Novel transparency information reveals that this good news doesn’t always translate into savings. Below, we rely on a unique data set from Turquoise Health to examine how much four national commercial health plans—Aetna, Anthem, Cigna, and UnitedHealthcare—paid ho
Drug Patent Watch
NOVEMBER 7, 2024
The rising cost of prescription drugs has become a significant public health concern, with millions of Americans struggling to afford their medications. One crucial factor in mitigating this issue is the increased use of generic drugs. Generic drugs have been instrumental in reducing healthcare costs, and their impact cannot be overstated.
STAT
NOVEMBER 8, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We expect to continue the never-ending quest to manicure the Pharmalot grounds, promenade with the official mascots, and catch up on napping. We also hope to hold another listening party, where the rotation will likely include this , this , this , this and this.
Express Pharma
NOVEMBER 4, 2024
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. “We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation, as well as confirming certificates of analysis,” the company said.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
PharmaVoice
NOVEMBER 7, 2024
Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.
Drug Patent Watch
NOVEMBER 6, 2024
Developing a Risk Management Plan (RMP) for generic drugs is a crucial step in ensuring the safety and efficacy of these medications. An RMP provides detailed information on a medicine’s safety profile, measures to prevent or minimize risks, and plans for ongoing safety monitoring and evaluation.
STAT
NOVEMBER 4, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so predictable routine of online meetings, phone calls, and deadlines has returned. But you knew this would happen, yes? The world, such as it is, continues to spin. So to cope, we are brewing a cup of stimulation in the Pharmalot cafeteria.
Med Ed 101
NOVEMBER 3, 2024
There are two agents that are frequently used in alcohol use disorder. Acamprosate and naltrexone have distinct advantages and disadvantages in the treatment of alcohol use disorder. In this article, we will compare the clinical benefits and risks of acamprosate vs naltrexone. What do the guidelines say? Both naltrexone and acamprosate are considered first-line treatments […] The post Acamprosate vs Naltrexone – Clinical Comparison appeared first on Med Ed 101.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
pharmaphorum
NOVEMBER 5, 2024
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.The new capsule formulation of the antibiotic minocycline hydrochloride has been cleared by the US regulator to treat the inflammatory lesions caused by rosacea – which causes flushing or long-term redness and pustules on the face – in adults.
Drug Channels
NOVEMBER 7, 2024
Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers' preparation.
STAT
NOVEMBER 4, 2024
The word “Tuskegee” has long embodied the painful symbol of medical racism, epitomizing how ethnically uninformed research practices have harmed Black Americans. It is impossible to erase this painful history. But we — one of us working for Tuskegee University, the other for Southern Research — are working on an innovative project to create a future in which Black Americans participate more fully in clinical research and share in its benefits.
Expert insights. Personalized for you.
343 
Let's personalize your content